aldoxorubicin Report issue

Small molecule Experimental
AACT ChEMBL MeSH PubChem

Active Ingredient History

NOW
  • Now
Aldoxorubicin (INNO-206) is a tumor-targeted doxorubicin conjugate in development by CytRx. Specifically, it is the (6-maleimidocaproyl) hydrazone of doxorubicin. Essentially, this chemical name describes doxorubicin attached to an acid-sensitive linker.   Wikipedia

Chemistry

  • SMILES: COc1cccc2c1C(=O)c1c(O)c3c(c(O)c1C2=O)C[C@@](O)(/C(CO)=N/NC(=O)CCCCCN1C(=O)C=CC1=O)C[C@@H]3O[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1.Cl
  • InChIKey: NGKHWQPYPXRQTM-UKFSEGPMSA-N
  • Mol. Mass: 787.22
  • ALogP: 0.39
  • ChEMBL Molecules:
    aldoxorubicin hydrochloride  
    aldoxorubicin  
More Chemistry

Pharmacology

Alternative names

aldoxo | aldoxorubicin | doxo-emch | inno-206

Organizations (30)

Research & Development (30)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (0)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (37)

Approved Indications (0)

Experimental Indications - Clinical Trial Phases 1-4 (37)


 

Acquired Immunodeficiency Syndrome (Phase 2)

Breast Neoplasms (Phase 2)

Carcinoma, Hepatocellular (Phase 1/Phase 2)

Carcinoma, Non-Small-Cell Lung (Phase 2)

Carcinoma, Squamous Cell (Phase 1/Phase 2)

Carcinoma, Transitional Cell (Phase 2)

Chordoma (Phase 1/Phase 2)

Colorectal Neoplasms (Phase 1/Phase 2)

Down Syndrome (Phase 3)

Glioblastoma (Phase 2)

Hamartoma (Phase 3)

HIV Infections (Phase 2)

Hodgkin Disease (Phase 3)

Leiomyosarcoma (Phase 3)

Leukemia (Phase 3)

Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative (Phase 2)

Liposarcoma (Phase 3)

Lymphoma (Phase 2/Phase 3)

Lymphoma, AIDS-Related (Phase 1)

Lymphoma, B-Cell (Phase 2/Phase 3)

Lymphoma, Follicular (Phase 1/Phase 2)

Lymphoma, Large B-Cell, Diffuse (Phase 3)

Lymphoma, Large-Cell, Immunoblastic (Phase 3)

Lymphoma, Non-Hodgkin (Phase 3)

Lymphoma, T-Cell (Phase 1/Phase 2)

Neoplasm Metastasis (Phase 3)

Neoplasms (Phase 2/Phase 3)

Pancreatic Neoplasms (Phase 2)

Plasmablastic Lymphoma (Early Phase 1)

Precursor B-Cell Lymphoblastic Leukemia-Lymphoma (Phase 3)

Sarcoma (Phase 2)

Sarcoma, Kaposi (Phase 2)

Small Cell Lung Carcinoma (Phase 2)

Testicular Neoplasms (Phase 3)

Thyroid Neoplasms (Phase 2)

Triple Negative Breast Neoplasms (Phase 1/Phase 2)

Urinary Bladder Neoplasms (Phase 2)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 44
  • # of Trial Organizations: 30

Trials by Phase

Trial Phase Start Date Organizations Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue